CliffBio
small molecule

SILDENAFIL CITRATE

SILDENAFIL CITRATE

Loss of exclusivity—loss of exclusivity
CompanyTris. →See this company's full patent-cliff portfolio

Drug detail

Brand nameSILDENAFIL CITRATE
Active ingredientSILDENAFIL CITRATE
StrengthEQ 10MG BASE/ML
Dosage formFOR SUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2021
Marketing statusDISCN

More from Tris.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

SILDENAFIL CITRATE patent cliff — loss of exclusivity — | CliffBio